Notably, in both studies [15,62], cfDNA levels appeared to outperform traditional serum markers such as AFP, AFP-L3 and des-gamma-carboxy prothrombin (DCP) in accurately reflecting tumor burden and therapeutic response. The gene discussed is AFP; the disease is neoplasm.